Urologic Oncology: Seminars and Original Investigations
Original articleRandomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study☆
References (25)
Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma
J Urol
(1982)- et al.
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized study with crossover design
J Urol
(1985) - et al.
A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers
J Urol
(1986) - et al.
A randomised prospective study comparing Intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa, pTl tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group
Eur J Cancer.
(1993) - et al.
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
J Chron Dis
(1981) - et al.
Designs for group sequential tests
Controlled Clinical Trials
(1984) - et al.
Fatal sepsis following Intravesical Bacillus Calmette-Guerin administration for bladder cancer
J Urol
(1990) - et al.
Bone marrow suppression after intravesical mitomycin C treatment
J Urol
(1986) - et al.
A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: Is it effective?
J Urol
(1991) Carcinoma in situ
Urol Clin N Amer
(1992)
Intravesical therapy comparing BCG, Adriamycin, and Thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study
Progress in Clinical and Biological Research
A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the Bladder
N Engl J Med
Cited by (119)
The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non–muscle-invasive bladder cancer: A network meta-analysis
2023, Urologic Oncology: Seminars and Original InvestigationsIntravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG
2022, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :After a median 15 month follow up, the 2-year RFS was dismal in both the gemcitabine (19%) and BCG (3%) groups. A multitude of other salvage therapy studies have been reported, including gemcitabine [22], mitomycin C [23], docetaxel [24], epirubicin [25], and gemcitabine with mitomycin C [26,27], but none included a pure population that received a single BCG induction course; rather, all assessed mixed cohorts with heterogeneous stage and prior treatment history. Our study is the first to assess outcomes of Gem/Doce specifically in the subset of patients who recur after a single induction course of BCG.
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer
2021, Urologic Oncology: Seminars and Original InvestigationsThe expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1
2018, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :Although the precise mechanism of action of BCG immunotherapy remains the subject of continued investigation, it is believed to function by activating both the innate and adaptive immune systems [7]. Intravesical BCG has been validated by multiple randomized controlled trials as a superior therapy to intravesical chemotherapy including mitomycin and epirubicin [8–11]. Since its introduction nearly 4 decades ago, BCG is still considered to be one of the most successful immunotherapy agents for any solid malignancy [12].
- ☆
This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA46113, CA22433 CA13612, CA42777, CA46441, CA46282, CA13238, CA45560, CA20319, CA27057, CA16385, CA28862, CA35192, CA35431, CA12213, CA22411, CA35090, CA32734, CA35178, CA35281, CA14028, CA35261, CA35117, CA45450, CA52420, CA37981, CA04919, CA36020, CA38926, CA32102, CA49957, CA21076.